Ekso Bionics® to Present at WearRAcon 2017 in Beijing, China
September 12 2017 - 8:00AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), an industry leader in
exoskeleton technology for medical and industrial use, today
announced that Thomas Looby, the company’s President and Chief
Executive Officer, will be a keynote speaker on September 14th at
WearRAcon China, which is being held in conjunction with the China
Disabled Persons’ Federation Conference at the National Convention
Center in Beijing, China from September 13-15, 2017.
During the keynote address, Mr. Looby will
provide a corporate overview of the Company’s medical division,
EksoHealth, including clinical benefits of the EksoGT™, a wearable
exoskeleton device designed for stroke and spinal cord injury
rehabilitation. In addition, the presentation will highlight the
Company's EksoWorks products, like the EksoZeroG™ and EksoVest™,
which are designed to offer construction and industrial workers
protection and support against fatigue and injury by reducing the
strain from high-frequency and long-duration
activities.
“We are thrilled to be presenting at WearRAcon
in China, which provides Ekso Bionics with visibility in a country
with the world’s largest number of stroke and spinal cord injury
patients,” said Mr. Looby. “The EksoGT enables mobility for
patients earlier in their recovery process than conventional
rehabilitation, so this conference marks an important milestone
towards our goal of changing lives around the world with our
proprietary exoskeleton technologies.”
WearRAcon is an annual event organized by the
Wearable Robotics Association (WearRA), the only professional
association dedicated to entrepreneurs, businesses and academics
fueling the wearable robotics industry. WearRAcon China will bring
together more than 300 attendees from across the world to attend
cutting-edge presentations and robotics demonstrations, as well as
provide opportunities to network with those creating and using
wearable robotic devices in the quickly growing Asian market.
The China Disabled Persons’ Federation,
established in 1988, is a national umbrella organization for
persons with diverse disabilities. The organization’s mission is to
promote the full participation of persons with disabilities in
society equally with others, ensure that persons with disabilities
share in the material and cultural achievements of society, and
foster humanitarianism across society as a whole.
For more information about Ekso Bionics or the
EksoGT, visit www.eksobionics.com.
About EksoGT™EksoGT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of a
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently, and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 185
rehabilitation institutions around the world.
About Ekso Bionics® Ekso
Bionics is a leading developer of exoskeleton solutions that
amplify human potential by supporting or enhancing strength,
endurance and mobility across medical, industrial and defense
applications. Founded in 2005, the company continues to build upon
its unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, changes resulting from the Company’s finalization of
its financial statements for and as of the period and year ended
December 31, 2016, information or new changes in facts or
circumstances that may occur prior to the filing of the Company’s
Annual Report on Form 10-K that are required to be included
therein, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie
Yamond917-371-2320cyamond@lazarpartners.com
Investor Contact:Matthew
Ventimiglia212-599-1265investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024